Endocrine Neoplasia Type 2B (MEN2B) harbor a germline mutation in the RET proto-oncogene (exon 16 codon 918). All individuals with MEN2B develop medullary thyroid carcinoma (MTC); metastatic or locally advanced MTC is unresponsive to cytotoxic chemotherapy or radiation.
Introduction
Medullary thyroid carcinoma (MTC) is a rare cancer arising from neural crest derived parafollicular C-cells within the thyroid gland. In childhood, the age adjusted incidence of MTC is < 0. 5 We designed a trial of vandetanib for children and adolescents with hereditary MTC to define the dose, toxicity profile, pharmacokinetics and anti-tumor activity. This is the first clinical trial of a RET inhibitor in children and adolescents with MTC. Utilizing intra-patient dose escalation meant that all patients with this very rare cancer were also evaluable for response and a therapeutic effect could be used to define the recommended dose.
MATERIALS and METHODS

Patients
Patients 5 to 18 years of age with measurable, locally advanced or metastatic, hereditary MTC were eligible. Other eligibility criteria are provided as Supplemental Data.
Protocol-specific exclusion criteria included elevated plasma metanephrines (evidence of pheochromocytoma); prolonged QTc, or requirement for medications known to prolong Consent and assent were obtained.
Study design
The primary objectives this Phase 1/ 2 trial were to assess the drug's safety, tolerance, and pharmacokinetics at two dose levels within the 100-300 mg/d dose range used in adults and to assess the anti-tumor activity of vandetanib in children and adolescents with measurable hereditary MTC.
Vandetanib was supplied by AstraZeneca Pharmaceuticals as 50 and 100 mg tablets and as a 10 mg/mL oral solution. The starting dose was 100 mg/m 2 /d (equivalent to 180 mg in an adult) administered orally, once daily, continuously for 28-day cycles.
Because of the limited safety data available in the pediatric population, adolescents (13-18 years) were enrolled prior to children (5-12 years) using a 3+3 design in each age group. To ensure safety and tolerance at steady state drug concentrations, toxicity was monitored during the initial 2 cycles of vandetanib prior to dose escalation. The maximum tolerated dose was the dose level at which <33% of patients in each age-based cohort (13-18 yr and 5-12 yr) experienced DLT during the first two treatment cycles. The recommended dose was based on overall tolerability and tumor response.
Pharmacokinetics
Vandetanib steady state pharmacokinetics were studied at the end of cycle 2.
Vandetanib was measured using a validated HPLC tandem mass spectrometry assay.(23) Pharmacokinetic parameters were calculated using non-compartmental methods.
Response Assessment
Radiographic response, quantified using RECIST (v1.0), was the primary endpoint Baseline biomarkers levels >2-fold above the upper limit of normal were required to be evaluable for biomarker response. A complete biomarker response was normalization of serum calcitonin or CEA level confirmed with a repeat measurements ≥4 weeks later, and a partial response was a ≥50% decrease from baseline confirmed ≥4 weeks later. Clinical benefit was evaluated using a patient reported outcome in patients with calcitonin-related diarrhea. Patients completed a daily diary including the number and consistency (formed, loose, or watery) of stools. Patients with 5 or more watery stools per day at baseline were evaluable for this endpoint. A complete response was defined as an average of 0-2 formed stools per day for a period of ≥4 weeks, and a partial response was defined as a ≥50% decrease in the average stool frequency relative to baseline and a change in stool consistency from watery to loose or formed for a period of ≥4 weeks.
Statistical Methods
The phase 2 objective was to determine whether the response rate to vandetanib in children and adolescents with hereditary MTC was comparable to the preliminary response rate of 30% in adults. 
RESULTS
Patient Characteristics
Between July 2007 and July 2011, 16 patients were accrued to this study at the NIH Clinical Center, 10 in the adolescent cohort (age 13-18 years) and 6 in childhood cohort (age 5-12 years). Patient characteristics are presented in Table 1 . All patients harbored a germline RET mutation in codon 918 except patient 03 who had a mcg•h/mL. All subjects achieved steady state. The average ± standard deviation C ss was 0.73±0.14 mcg/mL (Supplemental Figure 1) . The small sample size, low frequency of toxicity and progression of disease precluded formal correlations.
Response
All 15 subjects with M918T RET germline mutations experienced a decrease tumor size ( Figure 3 and 4) , and 7/15 achieved a confirmed partial response (objective response rate 47%; 95%CI, 21%, 73%). The overall objective response rate was 7/16 (44%; 95% CI, 20%, 70%). The number of cycles to achieve a partial response was 6 (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) . Two patients who achieved PR (subject 01 and 04) subsequently had progressive disease after 44 or 48 cycles of vandetanib, one patient with best response of stable disease (subject 07) developed a new metastatic lesion in bone after 28 cycles. One patient discontinued therapy with 25% decrease in tumor diameter (stable disease) after 29 cycles. For seven patients with confirmed partial responses, only one had bone metastases. Eleven patients remain on protocol therapy. and anti-tumor activity was impractical. We developed an innovative trial design to simultaneously determine the recommended dose using intra-patient dose escalation and anti-tumor activity of vandetanib, and restricted enrollment to patients with mutated RET proto-oncogene and measureable MTC. Dose escalation was limited to 2 dose levels with evidence of activity in adults with MTC. Safety was maintained by enrolling adolescents prior to children and by requiring DLT evaluation period to extent for 2 cycles to ensure steady state drug concentrations had been achieved and tolerated.
In adults with advanced solid tumors receiving vandetanib for 2.7 (0.1-14) months, the maximum tolerated and recommended dose of vandetanib was 300 mg daily. In the randomized phase 3 trial in adults with MTC, the median duration of vandetanib administration was 22.5 months, 35% required dose reductions for toxicity and one-third discontinued therapy due to an adverse event. 
